The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial
Runcaciguat improved albuminuria in patients with CKD, irrespective of concomitant SGLT2i. Runcaciguat was well tolerated. sGC activation may represent a novel kidney-protective treatment in CKD patients (funded by Bayer AG; ClinicalTrials.gov number, NCT04507061).
Authors
- Dirk Thomas (ORCID: https://orcid.org/0000-0002-0061-1632)
- Ron T. Gansevoort (ORCID: https://orcid.org/0000-0002-3223-0906)
- Frauke Friedrichs (ORCID: https://orcid.org/0009-0002-7005-8964)
- Mario Berger (ORCID: https://orcid.org/0000-0002-9048-3928)
- Francisco Martínez Debén
- Marijn M. Speeckaert (ORCID: https://orcid.org/0000-0001-9183-4390)
- Karen Paraschin (ORCID: https://orcid.org/0009-0007-8320-1658)
- Stefan Klein (ORCID: https://orcid.org/0000-0003-4449-6784)
- Roland E. Schmieder
- David Collins. Wheeler (ORCID: https://orcid.org/0000-0003-0745-3478)
Institutions
- Universidade da Coruña (ES)
- University Medical Center Groningen (NL)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Ghent University Hospital (BE)
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Erlangen (DE)
- University College London (GB)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1093/ndt/gfae261
- Citations
- 16
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 5.43
Funders
- Bayer